Clinical Trial

A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

Completed Phase 3
View on ClinicalTrials.gov →
Summary
This is a clinical trial assessing the safety, tolerability and pharmacokinetics (PK) of an investigational drug, VRDN-003, in participants with TED (Thyroid Eye Disease)
Protocol Amendment History 3 changes
critical Trial completed 2026-06-26
notable Primary completion moved earlier: 2026-07 -> 2026-05-28 2026-06-26
minor Completion moved earlier: 2026-11 -> 2026-05-28 2026-06-26
Trial Details
NCT Number NCT07155668
Lead Sponsor Viridian Therapeutics, Inc.
Conditions Thyroid Eye Disease
Enrollment 87 participants
Start Date 2025-07-01
Primary Completion 2026-05-28 (estimated)
Study Completion 2026-05-28 (estimated)
Updated on ClinicalTrials.gov 2026-06-25